Hormonal therapy continues to be the treatment of first choice for metastatic people with endocrine-responsive breast cancer (LoE 1a A, Back ++). The sequential use on the available medicines is determined by the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is usually recommended Eve